FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for AD


InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332.

ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatment of patients with moderate-to-severe atopic dermatitis (AD), demonstrating an outstanding efficacy and safety profile, according to InnoCare. ICP-332 showed better efficacy profile across different classes/MoAs of therapies for the treatment of AD patients (not a head-to-head comparison). The detailed data was presented at the 2024 American Academy of Dermatology (AAD) annual meeting as a late-breaking oral presentation.

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is a kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases.

"InnoCare is dedicated to targeting the global frontier in autoimmune therapy by focusing on B-cell and T-cell pathways," Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said in a company news release. "We have developed robust pipeline of differentiated therapeutics for autoimmune disease with significant market potential worldwide, including orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor), and ICP-923 (IL-17 small molecule inhibitor). We are committed to accelerating clinical development and look forward to our innovative drugs benefiting patients with autoimmune diseases as early as possible."

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free